Conditions: Uterine Hemorrhage Contraception
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: yes

Brief summary:
The specific aims are to determine if more women using Etonogestrel (ENG) contraceptive implants who report a bleeding-spotting episode of at least seven days will stop bleeding within 3 days of beginning a 14-day course of combined oral hormonal steroids, as compared to women receiving 14 days of placebo.

Detailed description:
The ENG contraceptive implant (Implanon/Nexplanon®), is a silicone- free, single rod subdermal contraceptive implant that contains 68 mg of etonogestrel, is approved for use for three years, and is one of the most effective forms of contraception available (1). ENG contraceptive implants are easily inserted and removed (1,2), offer quick return to fertility (2), are cost-effective and cost-saving (3,4) and offer non-contraceptive benefits such as improvement in pain for patients with complaints of dysmenorrhea (5).

Hypothesis: Women using ENG contraceptive implants who report a bleeding-spotting episode of at least seven days will be more likely to stop bleeding within 3 days of beginning a 14-day course of combined oral hormonal steroids compared to women receiving 14 days of placebo.

Arms:
arm 1: Placebo Sugar Pill arm 2: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill

Interventions: intervention 1: Combined Oral Contraceptive Pill intervention 2: Placebo Sugar Pill
Intervention descriptions: intervention 1: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill intervention 2: Placebo Sugar Pill

Protocol document: